相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma
A. Ray et al.
LEUKEMIA (2018)
ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation
Ueihuei Peng et al.
ONCOLOGY REPORTS (2017)
Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV
Peipei Xing et al.
ONCOTARGET (2017)
Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma
Fumito Abe et al.
ONCOTARGET (2017)
Histone deacetylase inhibitors interfere with angiogenesis by decreasing endothelial VEGFR-2 protein half-life in part via a VE-cadherin-dependent mechanism
Igor Hrgovic et al.
EXPERIMENTAL DERMATOLOGY (2017)
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
Yuankai Shi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Role of epigenetics-microRNA axis in drug resistance of multiple myeloma
Nasrin Rastgoo et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair
Ana-Alicia Lopez-Iglesias et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ≤ 30% blasts
G. Garcia-Manero et al.
LEUKEMIA (2017)
Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)
G. Bug et al.
LEUKEMIA (2017)
Diallyl trisulfides, a natural histone deacetylase inhibitor, attenuate HIF-1 synthesis, and decreases breast cancer metastasis
Zhonghong Wei et al.
MOLECULAR CARCINOGENESIS (2017)
Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma
Paul G. Richardson et al.
PHARMACOLOGICAL RESEARCH (2017)
Targeting growth hormone receptor in human melanoma cells attenuates tumor progression and epithelial mesenchymal transition via suppression of multiple oncogenic pathways
Reetobrata Basu et al.
ONCOTARGET (2017)
PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison
Joel C. Sunshine et al.
CLINICAL CANCER RESEARCH (2017)
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dan T. Vogl et al.
CLINICAL CANCER RESEARCH (2017)
Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells
Lubna Wasim et al.
BIOMEDICINE & PHARMACOTHERAPY (2016)
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
Toshio Shimizu et al.
INVESTIGATIONAL NEW DRUGS (2016)
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial
Andrew J. Yee et al.
LANCET ONCOLOGY (2016)
Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma
Nicola Amodio et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Essential role of HDAC6 in the regulation of PD-L1 in melanoma
M. Lienlaf et al.
MOLECULAR ONCOLOGY (2016)
A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors
Ning Jin et al.
ONCOLOGIST (2016)
Clinical characteristics and prognostic indicators for metastatic melanoma: data from 446 patients in north China
Mengze Hao et al.
TUMOR BIOLOGY (2016)
BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion
Alexandra M. Blee et al.
ONCOTARGET (2016)
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
Haeseong Park et al.
ONCOTARGET (2016)
MIIP accelerates epidermal growth factor receptor protein turnover and attenuates proliferation in non-small cell lung cancer
Jing Wen et al.
ONCOTARGET (2016)
AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells
Sherif Abdelhamed et al.
JOURNAL OF CANCER (2016)
Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma
Y. Shi et al.
ANNALS OF ONCOLOGY (2015)
Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death
Yuko Mishima et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Advances in targeted therapy for unresectable melanoma: New drugs and combinations
Mengze Hao et al.
CANCER LETTERS (2015)
Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma
Jennifer E. Amengual et al.
CLINICAL CANCER RESEARCH (2015)
STAT3 Association with Microtubules and Its Activation Are Independent of HDAC6 Activity
Bing Yan et al.
DNA AND CELL BIOLOGY (2015)
Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma
Hiroshi Nakashima et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation
K. V. Woan et al.
MOLECULAR ONCOLOGY (2015)
HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor Entities
Emily Koeneke et al.
CELLS (2015)
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma
Francine Foss et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
HDAC-inhibitor (S)-8 disrupts HDAC6-PP1 complex prompting A375 melanoma cell growth arrest and apoptosis
Manjola Balliu et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2015)
HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers
Preeti Putcha et al.
BREAST CANCER RESEARCH (2015)
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer
Yifan Tu et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
HDAC6 regulates neuroblastoma cell migration and may play a role in the invasion process
Linlin Zhang et al.
CANCER BIOLOGY & THERAPY (2014)
Paxillin inhibits HDAC6 to regulate microtubule acetylation, Golgi structure, and polarized migration
Nicholas O. Deakin et al.
JOURNAL OF CELL BIOLOGY (2014)
A Novel Role for Histone Deacetylase 6 in the Regulation of the Tolerogenic STAT3/IL-10 Pathway in APCs
Fengdong Cheng et al.
JOURNAL OF IMMUNOLOGY (2014)
被撤回的出版物: IN Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells (Retracted article. See vol. 18, pg. 1181, 2019)
Girija Dasmahapatra et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells
Fengdong Cheng et al.
MOLECULAR IMMUNOLOGY (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Tubulin hyperacetylation is adaptive in cardiac proteotoxicity by promoting autophagy
Patrick M. McLendon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition
Maj-Linda Selenica et al.
ALZHEIMERS RESEARCH & THERAPY (2014)
Histone deacetylase 6 and cytoplasmic linker protein 170 function together to regulate the motility of pancreatic cancer cells
Dengwen Li et al.
PROTEIN & CELL (2014)
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
Hua Yu et al.
NATURE REVIEWS CANCER (2014)
PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
Paul G. Richardson et al.
BLOOD (2013)
Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up
Eugenia Tsai et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial
Madeleine Duvic et al.
EUROPEAN JOURNAL OF CANCER (2013)
Different roles of PD-L1 and FasL in immunomodulation mediated by human placenta-derived mesenchymal stem cells
Yan-zheng Gu et al.
HUMAN IMMUNOLOGY (2013)
The Role of HDAC6 in Alzheimer's Disease
Ling Zhang et al.
JOURNAL OF ALZHEIMERS DISEASE (2013)
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
Meletios Dimopoulos et al.
LANCET ONCOLOGY (2013)
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies
D. J. DeAngelo et al.
LEUKEMIA (2013)
Development and therapeutic impact of HDAC6-selective inhibitors
Sabrina Dallavalle et al.
BIOCHEMICAL PHARMACOLOGY (2012)
A novel GRK2/HDAC6 interaction modulates cell spreading and motility
Vanesa Lafarga et al.
EMBO JOURNAL (2012)
Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth
Joel A. Bergman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
HDAC6 Regulates Epidermal Growth Factor Receptor (EGFR) Endocytic Trafficking and Degradation in Renal Epithelial Cells
Wei Liu et al.
PLOS ONE (2012)
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma
Brian A. Walker et al.
BLOOD (2011)
Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim
Yun Dai et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
The Role of HDAC6 in Cancer
Grace I. Aldana-Masangkay et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
HDAC6 and Ubp-M BUZ Domains Recognize Specific C-Terminal Sequences of Proteins
Ryan L. Hard et al.
BIOCHEMISTRY (2010)
Interplay between microRNAs and the epigenetic machinery: An intricate network
Marilena V. Iorio et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2010)
The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition
Chiara Giommarelli et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2010)
CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin
Sara A. Wickstroem et al.
EMBO JOURNAL (2010)
The Microtubule-associated Histone Deacetylase 6 (HDAC6) Regulates Epidermal Growth Factor Receptor (EGFR) Endocytic Trafficking and Degradation
Ya-Sheng Gao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
Jiahuai Tan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2010)
Drosophila Histone Deacetylase 6 Protects Dopaminergic Neurons against α-Synuclein Toxicity by Promoting Inclusion Formation
Guiping Du et al.
MOLECULAR BIOLOGY OF THE CELL (2010)
HDAC family: What are the cancer relevant targets?
Olaf Witt et al.
CANCER LETTERS (2009)
Genomic Screening for Genes Silenced by DNA Methylation Revealed an Association between RASD1 Inactivation and Dexamethasone Resistance in Multiple Myeloma
Masanori Nojima et al.
CLINICAL CANCER RESEARCH (2009)
Impact of heat-shock protein 90 on cancer metastasis
Shinji Tsutsumi et al.
FUTURE ONCOLOGY (2009)
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4(+)CD25(Hi) regulatory T cells
Wenshi Wang et al.
INTERNATIONAL IMMUNOLOGY (2009)
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
Richard L. Piekarz et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair
P. Maiso et al.
LEUKEMIA (2009)
STATs in cancer inflammation and immunity: a leading role for STAT3
Hua Yu et al.
NATURE REVIEWS CANCER (2009)
Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
Jennifer S. Carew et al.
CANCER LETTERS (2008)
The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis
Yi-Shan Lee et al.
CANCER RESEARCH (2008)
Ubiquitin Proteasome System Stress Underlies Synergistic Killing of Ovarian Cancer Cells by Bortezomib and a Novel HDAC6 Inhibitor
Martina Bazzaro et al.
CLINICAL CANCER RESEARCH (2008)
The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration
Jinmin Gao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination
C. Boyault et al.
ONCOGENE (2007)
HDAC6 modulates cell motility by altering the acetylation level of cortactin
Xiaohong Zhang et al.
MOLECULAR CELL (2007)
Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS
Udai Bhan Pandey et al.
NATURE (2007)
Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-κB signaling
Ramin Massoumi et al.
CELL (2006)
Modulating molecular chaperone Hsp90 functions through reversible acetylation
S Aoyagi et al.
TRENDS IN CELL BIOLOGY (2005)
Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer
S Saji et al.
ONCOGENE (2005)
The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase
AI Marcus et al.
CANCER RESEARCH (2005)
Class II histone deacetylases:: from sequence to function, regulation, and clinical implication
XJ Yang et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
HDAC6 expression is correlated with better survival in breast cancer
ZH Zhang et al.
CLINICAL CANCER RESEARCH (2004)
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
A Kamal et al.
NATURE (2003)
Class II histone deacetylases: versatile regulators
E Verdin et al.
TRENDS IN GENETICS (2003)
Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation
SJ Haggarty et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Histone deacetylases (HDACs): characterization of the classical HDAC family
AJM De Ruijter et al.
BIOCHEMICAL JOURNAL (2003)
分享论文
